Apis Capital Advisors Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KEM
KEMET Corporation
KEM
|
+$2.39M |
| 2 |
AERI
Aerie Pharmaceuticals
AERI
|
+$1.32M |
| 3 |
DERM
Dermira, Inc.
DERM
|
+$750K |
| 4 |
Vicor
VICR
|
+$738K |
| 5 |
CCRD
CoreCard
CCRD
|
+$436K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
+$3.33M |
| 2 |
NovoCure
NVCR
|
+$2.68M |
| 3 |
I
INTELSAT S. A.
I
|
+$2.12M |
| 4 |
Silicon Motion
SIMO
|
+$2.03M |
| 5 |
Golar LNG
GLNG
|
+$1.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.13% |
| 2 | Technology | 9.62% |
| 3 | Consumer Discretionary | 6.96% |
| 4 | Energy | 6.21% |
| 5 | Industrials | 2.92% |
Similar funds
Apis Capital Advisors's Q1 2019 Portfolio in Review
As of Q1 2019, Apis Capital Advisors held 34 positions worth $82.9M, up 11% from $74.6M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Apis Capital Advisors withdrew a net $9.13M in Q1 2019, closing 3 positions and reducing 18 holdings. Its most notable exit was Electro Scientific Industries, an estimated $899K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 53% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Apis Capital Advisors opened a new position in Aerie Pharmaceuticals worth $1.43M.
- Apis Capital Advisors's largest Q1 2019 buy was Aerie Pharmaceuticals: 30,000 shares worth $1.43M.
- Apis Capital Advisors added most to KEMET Corporation in Q1 2019, an estimated $2.39M increase.
- Apis Capital Advisors's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $3.33M.
- Apis Capital Advisors fully exited Electro Scientific Industries in Q1 2019, selling an estimated $899K.
- Apis Capital Advisors's ten largest holdings make up 75% of its $82.9M portfolio in Q1 2019.
- Apis Capital Advisors opened 8 new positions and closed 3 in Q1 2019.
- Apis Capital Advisors's portfolio value rose 11% quarter-over-quarter to $82.9M.
Based on Apis Capital Advisors's 13F filing for Q1 2019, filed 7 May 2019.